Product Highlight - Rexulti

REXULTI^® is an atypical antipsychotic with unique binding profile on dopamine, serotonin and noradrenaline ^1,2
REXULTI^®, a balanced treatment with short- and long-term efficacy for schizophrenia in adult ^1,2
• REXULTI^® demonstrated significant improvement in PANSS score in patients with acute schizophrenia ¹
• 86.5% of patients remained relapse-free in a 52-week study²
• REXULTI^® maintained improvements in general functioning as measured by GAF²

PANSS = Positive And Negative Syndrome Scale; GAF = Global Assessment of Functioning

References:
1. Kane JM, Skuban A, Ouyang J et al. Schizophr Res. 2015 May;164(1-3):127-35.
2. Fleischhacker WW., Hobart M., Ouyang J. et al. Int J Neuropsychopharmacol. 2017 Jan 1; 20(1): 11–21.